Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-cash Items: 2016-2019

  • Akebia Therapeutics' Non-cash Items rose 59.87% to $3.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was $3.8 million, marking a year-over-year increase of 59.87%. This contributed to the annual value of $3.8 million for FY2019, which is 59.87% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Non-cash Items of $3.8 million as of Q4 2019, which was up 59.87% from $2.4 million recorded in Q4 2018.
  • Over the past 5 years, Akebia Therapeutics' Non-cash Items peaked at $21.9 million during Q4 2017, and registered a low of $2.4 million during Q4 2018.
  • Its 3-year average for Non-cash Items is $9.3 million, with a median of $3.8 million in 2019.
  • As far as peak fluctuations go, Akebia Therapeutics' Non-cash Items spiked by 110.13% in 2017, and later tumbled by 89.28% in 2018.
  • Quarterly analysis of 4 years shows Akebia Therapeutics' Non-cash Items stood at $10.4 million in 2016, then surged by 110.13% to $21.9 million in 2017, then plummeted by 89.28% to $2.4 million in 2018, then spiked by 59.87% to $3.8 million in 2019.
  • Its last three reported values are $3.8 million in Q4 2019, $2.4 million for Q4 2018, and $21.9 million during Q4 2017.